AccScience Publishing / IMO / Online First / DOI: 10.36922/IMO026210026
Cite this article
1
Download
36
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
PERSPECTIVE ARTICLE

Temporal genomic memory: A testable systems biology framework linking metabolic–epigenetic coupling to cancer initiation

Sherif Salah Abdul Aziz1* Khalid F. Kassem2 Mohamed Sherif Salah3
Show Less
1 Bacteriology Department, Faculty of Veterinary Medicine, Cairo University, Giza , Egypt
2 Department of Medicine, Faculty of Medicine, Cairo University, Kasr Al-Ainy , Egypt
3 Faculty of Dentistry, Future University in Cairo, Cairo , Egypt
Received: 20 May 2026 | Revised: 26 July 2026 | Accepted: 20 August 2026 | Published online: 28 August 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Cancer initiation has traditionally been explained by the progressive accumulation of somatic genetic alterations. Although this paradigm remains fundamental, increasing evidence indicates that long-term biological exposures including chronic inflammation, metabolic dysfunction, oxidative stress, mitochondrial adaptation, and immune dysregulation can produce persistent regulatory changes that are not fully explained by DNA sequence variation alone. Existing concepts such as epigenetic memory, metabolic memory, trained immunity, and adaptive cellular plasticity each describe important aspects of biological persistence but do not provide an integrated framework explaining how prolonged exposure histories may influence future oncogenic susceptibility. Here, we propose temporal genomic memory (TGM) as a testable systems biology framework describing how sustained biological experiences may be progressively integrated, compressed, and retained as persistent regulatory states through coordinated interactions among metabolic signaling, mitochondrial function, chromatin remodeling, regulatory RNA networks, and tissue-level immune adaptation. Unlike existing memory paradigms that primarily emphasize individual regulatory mechanisms, the proposed framework introduces regulatory compression as a conceptual process through which diverse biological signals are consolidated into latent molecular configurations capable of influencing future transcriptional responsiveness. Under permissive conditions such as aging, chronic inflammation, immune decline, or recurrent metabolic stress, these latent regulatory states may undergo molecular recall, thereby modifying cellular responses to subsequent biological challenges and potentially increasing oncogenic susceptibility in cooperation with established genetic and environmental factors. A conceptual mathematical representation is introduced to describe biological signal accumulation, regulatory compression, and recall activation while emphasizing its heuristic rather than predictive purpose. We further propose experimentally testable strategies based on chronic exposure, stress-withdrawal persistence, recall-challenge paradigms, and integrated multi-omics analyses to evaluate the hypothesis. Temporal genomic memory is not intended to replace the somatic mutation theory of cancer. Instead, it provides a complementary systems-level perspective integrating metabolic history, mitochondrial signaling, epigenetic regulation, and persistent transcriptional adaptation into a unified theoretical framework for investigating long-latency cancer initiation.

Keywords
Temporal genomic memory
Cancer initiation
Epigenetic memory
Mitochondrial signaling
Regulatory compression
Molecular recall
Systems biology
Oncogenic susceptibility
Funding
None.
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript.
References
  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834
  2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558. doi: 10.1126/science.1235122
  3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013
  4. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059
  5. Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2021;22(1):3-18. doi: 10.1038/s41576-020-0265-5
  6. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159. doi: 10.1056/NEJMra072067
  7. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27. doi: 10.1016/j.cell.2012.06.013
  8. Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N Engl J Med. 2018;378(14):1323-1334. doi: 10.1056/NEJMra1402513
  9. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10(5):295-304. doi: 10.1038/nrg2540
  10. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013;153(1):56-69. doi: 10.1016/j.cell.2013.03.004
  11. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab. 2012;16(1):9-17. doi: 10.1016/j.cmet.2012.06.001
  12. Dai Z, Ramesh V, Locasale JW. The evolving metabolic landscape of chromatin biology and epigenetics. Nat Rev Genet. 2020;21(12):737-753. doi: 10.1038/s41576-020-0270-8
  13. Boon R, Silveira GG, Mostoslavsky R. Nuclear metabolism and the regulation of the epigenome. Nat Metab. 2020;2(11):1190-1203. doi: 10.1038/s42255-020-00285-4
  14. Izzo LT, Affronti HC, Wellen KE. The bidirectional relationship between cancer epigenetics and metabolism. Annu Rev Cancer Biol. 2021;5:235-257. doi: 10.1146/annurev-cancerbio-070820-035832
  15. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205(10):2409-2417. doi: 10.1084/jem.20081188
  16. Netea MG, Quintin J, van der Meer JWM. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9(5):355-361. doi: 10.1016/j.chom.2011.04.006
  17. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. doi: 10.1126/science.1160809
  18. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211-218. doi: 10.1016/j.tibs.2015.12.001
  19. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47. doi: 10.1016/j.cmet.2015.12.006
  20. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669-680. doi: 10.1038/s41568-021-00378-6
  21. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-698. doi: 10.1038/nrc3365
  22. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science. 2011;333(6046):1109-1112. doi: 10.1126/science.1201940
  23. Martínez-Reyes I, Chandel NS. Mitochondrial tricarboxylic acid cycle metabolites control physiology and disease. Nat Commun. 2020;11:102. doi: 10.1038/s41467-019-13668-3
  24. Etchegaray JP, Mostoslavsky R. Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes. Mol Cell. 2016;62(5):695-711. doi: 10.1016/j.molcel.2016.05.029
  25. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516-531. doi: 10.1038/s41568-020-0273-y
  26. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:R115. doi: 10.1186/gb-2013-14-10-r115
  27. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505. doi: 10.1101/cshperspect.a019505
  28. Lee JE, Kim MY. Cancer epigenetics: Past, present and future. Semin Cancer Biol. 2022;83:4-14. doi: 10.1016/j.semcancer.2021.03.025
Share
Back to top
Innovative Medicines & Omics, Electronic ISSN: 3060-8740 Print ISSN: 3060-8910, Published by AccScience Publishing